Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

(2014) H. S. Rugo et al.   ANNALS OF ONCOLOGY

ESR1gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients

(2014) Joaquina Martínez-Galán et al.   BMC CANCER

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

(2013) Denise A. Yardley et al.   ADVANCES IN THERAPY

O1-030 * PHASE II STUDY OF PALBOCICLIB (PD-0332991) + LETROZOLE VS LETROZOLE ALONE IN FIRST-LINE ER + /HER2- ADVANCED BREAST CANCER

(2013) R. S. Finn et al.   ANNALS OF ONCOLOGY

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

(2013) Howard A. Burris et al.   CANCER

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

(2013) F. Andre et al.   CLINICAL CANCER RESEARCH

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

(2013) A. D. Leo et al.   JNCI-Journal of the National Cancer Institute

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

(2013) Stephen RD Johnston et al.   LANCET ONCOLOGY

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

(2013) John FR Robertson et al.   LANCET ONCOLOGY

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

1st International consensus guidelines for advanced breast cancer (ABC 1)

(2012) F. Cardoso et al.   BREAST

Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance

(2012) Rocío García-Becerra et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

(2012) Rita S. Mehta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

(2012) Patricia Mucci LoRusso   ONCOLOGY

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

(2011) Mario Giuliano et al.   BREAST

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study

(2011) C. K. Osborne et al.   CLINICAL CANCER RESEARCH

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY